Pfizer-BioNTech’s corona vaccine is effective for children between the ages of 5 and 11, the vaccine manufacturers reported on Monday. Now they will try to get approval for use on children in the United States.
Children receive a smaller dose, about a third of what adults get. Clinical studies show that after two doses, the vaccine is as effective as in teenagers and young adults, the companies stated in a statement.
“The vaccine gave a robust immune response in children aged 5 to 11 years,” the statement said.
The dose the children receive should also give similar or fewer temporary side effects than what teenagers may experience, such as soreness in the arm and fever.
Pfizer-BioNTech will apply for emergency approval for use on children in the United States by the end of September. After that, they will also request approval in the EU and the UK.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at firstname.lastname@example.org